A Case of Castration-Resistant Prostate Cancer with Fatal Convulsive Seizure after Administration of Enzalutamide

Enzalutamide, an androgen receptor antagonist, is a standard drug for the treatment of castrationresistant prostate cancer. A 77-year-old man developed a seizure after administration of enzalutamide. The patient presented with general fatigue and high fever approximately 5 weeks after oral administr...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 63(2017), 10 vom: 05. Okt., Seite 431-433
1. Verfasser: Iwanishi, Toshichika (VerfasserIn)
Weitere Verfasser: Yumiba, Satoru, Koida, Youhei, Kobayashi, Masao, Komori, Kazuhiko, Ono, Yutaka
Format: Online-Aufsatz
Sprache:Japanese
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Case Reports Journal Article Review Prostate cancer Seizure Benzamides Nitriles Phenylthiohydantoin 2010-15-3 enzalutamide 93T0T9GKNU
Beschreibung
Zusammenfassung:Enzalutamide, an androgen receptor antagonist, is a standard drug for the treatment of castrationresistant prostate cancer. A 77-year-old man developed a seizure after administration of enzalutamide. The patient presented with general fatigue and high fever approximately 5 weeks after oral administration of enzalutamide. Several days later, a seizure attack occurred at home, resulting in cardiopulmonary arrest. The patient was taken to the hospital emergency room but could not be resuscitated. We described a 63-year-old man who was diagnosed with clinical T1c prostate cancer, with a Gleason score of 6 (3+3), and a preoperative prostate-specific antigen (PSA) level of 5. 27 ng/ml. Radical prostatectomy(RP) was performed and final pathologyshowed Gleason score 3+4, pT2c with negative surgical margin. In spite of suggested surgical radicality, PSA was 3.32, 4.78, 5.93 ng/ml, at 1, 2, and 3 months after RP, respectively. However, radiological investigation revealed no metastasis. Because of this clinical discrepancy, we checked the PSA-α1-antichemotrypsin level and found it to be ≦0.1 ng/ml. From these results, false PSA elevation caused byinterference of positive heterophilic antibodies was suggested and demonstrated byseveral immunoassays
Beschreibung:Date Completed 24.01.2018
Date Revised 04.12.2021
published: Print
Citation Status MEDLINE
ISSN:0018-1994
DOI:10.14989/ActaUrolJap_63_10_431